论文部分内容阅读
目的探讨并分析使用艾迪注射液对老年白血病进行临床治疗的效果。方法选取2013年2月-2015年3月医院就诊并接受治疗的80例老年白血病患者病例资料,依据治疗方式不同将其分为对照组和观察组各40例,对照组采用常规治疗,观察组在常规基础上加用艾迪注射液治疗,比较2组治疗临床效果。结果观察组治疗后CD8+、CD4+、CD3+三项T细胞亚群数量明显优于对照组,差异具有统计学意义(P<0.05);观察组血液毒性、肝功能及肾功能不良反应发生率分别为15.00%、5.00%及2.50%明显少于对照组的40.00%、30.00%及27.50%,差异有统计学意义(P<0.05)。结论使用艾迪注射液治疗老年白血病,效果显著,不良反应发生率较少,且见效快,值得临床推广应用。
Objective To investigate and analyze the effect of Aidi injection on clinical treatment of elderly patients with leukemia. Methods The data of 80 elderly patients with leukemia treated at the hospital from February 2013 to March 2015 were selected and divided into a control group and an observation group of 40 cases according to different treatment methods. The control group received routine treatment. The observation group Aidi injection was added on a routine basis and the clinical effects of the two groups were compared. Results The number of CD8+, CD4+, and CD3+ T cell subsets in the observation group was significantly better than that in the control group (P<0.05). The incidence of hematologic toxicity, liver function, and renal dysfunction in the observation group were 15.00%, 5.00%, and 2.50% were significantly lower than the 40.00%, 30.00%, and 27.50% of the control group, with a significant difference (P<0.05). Conclusion The use of Aidi injection in the treatment of elderly patients with leukemia has a significant effect, the incidence of adverse reactions is less, and it is effective, and it is worthy of clinical application.